cemadotin: a synthetic derivative of dolostatin 15; interacts with microtubules & inhibits mitosis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9812632 |
| CHEMBL ID | 2104387 |
| SCHEMBL ID | 18768 |
| MeSH ID | M0249304 |
| Synonym |
|---|
| cemadotin |
| n,n-dimethyl-l-valyl-l-valyl-n-methyl-l-valyl-l-prolyl-n-benzyl-l-prolinamide |
| nsc d-669356 |
| l-prolinamide, n,n-dimethyl-l-valyl-l-valyl-n-methyl-l-valyl-l-prolyl-n-(phenylmethyl)- |
| unii-6sq8m7zsfv |
| 159776-69-9 |
| n,n-dimethyl-l-valyl-l-valyl-n-methyl-l-valyl-l-prolyl-l-prolinebenzylamide |
| cemadotin [inn] |
| lu103793 |
| lu-103793 |
| lu 103793 |
| CHEMBL2104387 |
| nsc-d-669356 |
| 6sq8m7zsfv , |
| cemadotin [who-dd] |
| SCHEMBL18768 |
| Q27265457 |
| CS-0007296 |
| HY-13589 |
Cemadotin is a derivative of natural anti-tumor peptide dolastatin-15; hence these compounds were docked against all three IAPs. It has potent antiproliferative and preclinical antitumor activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cemadotin is a derivative of natural anti-tumor peptide dolastatin-15; hence these compounds were docked against all three IAPs." | ( Molecular Dynamics simulations of Inhibitor of Apoptosis Proteins and identification of potential small molecule inhibitors. Anishetty, S; Jayakumar, J, 2014) | 1.12 |
| "Cemadotin is a synthetic analogue of dolastatin 15 with potent antiproliferative and preclinical antitumor activity." | ( A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Allen, LF; Clark, JW; Eder, JP; Fram, R; Kufe, DW; Lynch, TJ; Supko, JG; Velagapudi, R, 2000) | 1.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cemadotin did not inhibit the binding of vinblastine to tubulin, and, conversely, vinblastine did not inhibit the binding of cemadotin to tubulin." | ( Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Barlozzari, T; de Arruda, M; Jordan, MA; Panda, D; Walker, D, 1998) | 1.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||